Chronic Lymphocytic Leukemia
暫譯: 慢性淋巴細胞白血病

本書總結了有關慢性淋巴細胞白血病（CLL）的當前知識，考慮了最新的研究成果。所有方面均被考慮，包括病理生理學、臨床表現、診斷、預後、治療、隨訪以及併發症及其管理。讀者將找到有關各種預後標記的重要信息，以及有關不同診斷程序使用的實用指導。本書的一個關鍵重點是CLL治療模式的變化，隨著對病因學和病理生理學理解的進展，導致新潛在治療靶點的識別。一般治療概念被清晰地描述，並解釋了CLL的治療選擇如何依賴於疾病階段、年齡、表現狀態以及特定的基因異常。此外，還報告了針對疾病復發的一線治療策略，包括異基因幹細胞移植。除了CLL之外，本書還探討了T細胞前淋巴細胞白血病和T細胞大顆粒淋巴細胞白血病這兩種與CLL相關的罕見實體的診斷和治療。

Michael Hallek, MD, received his medical degree from the University of Munich, Germany, in 1985. From 1985 to 1990, he trained in pharmacology and internal medicine at that university and at the Technical University of Munich. He then spent two years as a research associate at the Dana Farber Cancer Institute at Harvard Medical School, Boston, USA, before returning to the University of Munich, where he continued his training in internal medicine and in hematology and oncology. From 1994 to 2005, he was head of the Gene Therapy Program at the Gene Center of the University of Munich and at the National Center for Research on Environment and Health (GSF), Munich. In 1994, he founded the German CLL Study Group (DCLLSG) and has remained its chairman until today. Since 2003, Dr. Hallek has been Professor of Medicine, Director, and Chair of the Department I of Internal Medicine at the University of Cologne. Since 2007, he has also been chairman of the Center for Integrated Oncology (CIO), the joint comprehensive cancer center of the Universities of Cologne and Bonn. In 2011, he became a member of the National Academy of Sciences (Leopoldina). Besides numerous awards, he has received the honour of the Ham-Wasserman Lecture during the American Society of Hematology in 2018. Since 2018, he has been chairman of the scientific committee of the European School of Haematology, Paris.

Barbara Eichhorst, MD, PhD, graduated from the Medical School of the University of Munich in 1997. She did her doctoral thesis in the field of hematology, evaluating signaling transduction pathways in Hodgkin cells. Dr. Eichhorst completed an internship at the Department III for Internal Medicine at Klinikum Großhadern of the University of Munich before becoming a consultant for internal medicine. She has worked at the University Hospital of Cologne since February 2005 and was appointed a consultant in hematology and internal oncology there in April 2006. She became assistant professor at the University of Cologne in December 2012 and is a consultant in Department I for Internal Medicine at the University Hospital of Cologne. Shortly after the foundation of the German CLL Study Group (GCLLSG) she became a member of its leading group, acting as principal investigator in several phase II and III trials evaluating treatment optimization in CLL. Since 2005 she has been secretary of the GCLLSG. Dr. Eichhorst has published a number of papers on the topic of treatment of CLL within clinical trials, and she is a globally recognized specialist in the field of CLL.

Daniel Catovsky, MD, DSc(Med), FRCPath, FMedSci, is Emeritus Professor and Fellow in the Division of Molecular Pathology at The Institute of Cancer Research, London, UK. Dr. Catovsky obtained his medical degree in Buenos Aires in 1961 and from 1967 worked under David Galton in the MRC Leukaemia Unit at the Hammersmith Hospital and Royal Postgraduate Medical School, where he was awarded a personal chair in hemato-oncology. In 1988 he became Head of Haematology at the Royal Marsden Hospital and The Institute of Cancer Research. A world authority on chronic adult leukemias, he has held visiting professorships in many countries, served on the editorial board of ten national and international journals, and published over 850 book chapters and papers in peer-reviewed journals. One of the key people who brought CLL, the most common adult leukemia, to the attention of the research community, he has been coordinator of the UK CLL Trials 1, 2, 3, 4, and 5. His work in hairy cell leukemia has helped to transform the prognosis for patients with this disease. He has served on a variety of review and advisory boards and has been President of the British Society of Haematology (1996-7) and of the European Research Initiative on CLL (ERIC) (2006-2009). He has received the BSH Medal for contributions to British hematology (2000) and the Binet-Rai medal for outstanding contributions to CLL research (2005).

邁克爾·哈雷克（Michael Hallek），醫學博士，於1985年獲得德國慕尼黑大學的醫學學位。從1985年到1990年，他在該大學及慕尼黑工業大學接受藥理學和內科醫學的訓練。隨後，他在美國波士頓的哈佛醫學院丹娜法伯癌症研究所擔任研究助理兩年，然後返回慕尼黑大學，繼續進行內科醫學及血液學和腫瘤學的訓練。從1994年到2005年，他擔任慕尼黑大學基因中心及慕尼黑國家環境與健康研究中心（GSF）基因治療計畫的負責人。1994年，他創立了德國慢性淋巴細胞白血病研究小組（DCLLSG），並至今擔任其主席。自2003年以來，哈雷克博士擔任科隆大學內科醫學系的醫學教授、主任及系主任。自2007年起，他還擔任科隆大學和波恩大學聯合綜合癌症中心（CIO）的主席。2011年，他成為德國國家科學院（Leopoldina）的成員。除了獲得眾多獎項外，他在2018年美國血液學會上獲得哈姆-瓦瑟曼講座的榮譽。自2018年以來，他一直擔任歐洲血液學學校（European School of Haematology，巴黎）科學委員會的主席。

巴巴拉·艾希霍斯特（Barbara Eichhorst），醫學博士，哲學博士，於1997年畢業於慕尼黑大學醫學院。她的博士論文研究血液學，評估霍奇金細胞中的信號轉導途徑。艾希霍斯特博士在慕尼黑大學格羅斯哈登醫院內科第三部門完成實習，隨後成為內科顧問。自2005年2月以來，她在科隆大學醫院工作，並於2006年4月被任命為該院血液學和內部腫瘤學的顧問。她於2012年12月成為科隆大學的助理教授，並在科隆大學醫院內科第一部門擔任顧問。在德國慢性淋巴細胞白血病研究小組（GCLLSG）成立不久後，她成為其領導小組的成員，並在多個評估慢性淋巴細胞白血病（CLL）治療優化的第二和第三期臨床試驗中擔任主要研究者。自2005年以來，她一直擔任GCLLSG的秘書。艾希霍斯特博士在臨床試驗中發表了多篇有關CLL治療的論文，是該領域全球公認的專家。

丹尼爾·卡托夫斯基（Daniel Catovsky），醫學博士，醫學科學博士，FRCPath，FMedSci，是英國倫敦癌症研究所分子病理學部的名譽教授和研究員。卡托夫斯基博士於1961年在布宜諾斯艾利斯獲得醫學學位，並於1967年在哈默史密斯醫院和皇家研究生醫學院的MRC白血病單位在大衛·高爾頓（David Galton）指導下工作，獲得血液腫瘤學的個人教授職位。1988年，他成為皇家馬斯登醫院和癌症研究所的血液學部門負責人。作為慢性成人白血病的世界權威，他在許多國家擔任訪問教授，並在十本國內外期刊的編輯委員會任職，發表了超過850篇書籍章節和同行評審的論文。他是將最常見的成人白血病——慢性淋巴細胞白血病（CLL）引起研究界關注的關鍵人物之一，並擔任英國CLL試驗1、2、3、4和5的協調員。他在多毛細胞白血病的研究中，幫助改善了該病患者的預後。他曾在各種審查和諮詢委員會任職，並擔任英國血液學會（1996-1997）和歐洲CLL研究倡議（ERIC）（2006-2009）的主席。他因對英國血液學的貢獻而獲得BSH獎章（2000年）和因對CLL研究的卓越貢獻而獲得比內-賴獎章（2005年）。